支气管肺发育不良的机制及糖皮质激素的防治研究进展  

The mechanism of bronchopulmonary dysplasia and the advancement of glucocorticoid in the prophylaxis and treatment of bronchopulmonary dysplasia

作　　者：周钊贤(综述) 容志惠(审校)[1] Zhou Zhaoxian;Rong Zhihui(Dapartment of Neonatology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030)

机构地区：[1]华中科技大学同济医学院附属同济医院新生儿科,武汉430030

出　　处：《国际儿科学杂志》2021年第4期231-234,共4页International Journal of Pediatrics

摘　　要：支气管肺发育不良是早产儿慢性呼吸系统疾病的主要病因。因其在早产儿中发病率高、预后差,预防和治疗方面的研究一直是新生儿医师关注的热点。针对其以肺部炎症持续性存在为特点的病理变化,糖皮质激素成为目前最为普遍使用的一种治疗药物。目前针对不同的糖皮质激素类型及给药方式进行了大量的临床研究,小剂量、短疗程的地塞米松在治疗支气管肺发育不良过程中具有独特的优势。该文对炎症在支气管肺发育不良发病中的作用以及糖皮质激素防治支气管肺发育不良的研究进展进行综述。Bronchopulmonary dysplasia(BPD)is the main cause of chronic respiratory diseases in preterm infants.The research on the prophylaxis and treatment of BPD has been a concern of neonatologists because of its high incidence and poor prognosis in preterm infants.Glucocorticoid is a major therapy in the treatment of BPD because the pathological changes of BPD are characterized by persistent lung inflammation.Until now,a large number of clinical studies including different types and administration methods of glucocorticoids have been conducted.Compared with other types of glucocorticoids,low-dose and short-course dexamethasone has its unique advantages in the treatment of BPD.This article reviews the role of inflammation in the pathogenesis of BPD and the research progress of glucocorticoids in the prophylaxis and treatment of BPD.

关 键 词：早产儿 支气管肺发育不良 糖皮质激素 

分 类 号：R72[医药卫生—儿科]